Page last updated: 2024-12-05

fast red b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fast Red B is a diazo dye used in histology and cytology for staining. Its chemical name is 2-benzenediazonium-4-nitrophenol. It is synthesized through the diazotization of 4-nitroaniline with sodium nitrite in acidic conditions. The resulting diazonium salt is then coupled with 2-naphthol to form the dye. Fast Red B reacts with tissue components, such as proteins, to form a red-colored complex. This staining property makes it useful for identifying specific cell types, tissues, and structures. It is also used in immunohistochemistry for visualizing antigens. The dye has a high affinity for tissue components and produces a bright, intense red color, making it suitable for microscopic observation.'

Fast Red B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fast red B : An organosulfonate salt composed from 2-methoxy-4-nitrobenzene-1-diazonium and 5-sulfonaphthalene-1-sulfonate in a 1:1 ratio. Used for demostrating enterochromaffin in carcinoid tumours. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7337
CHEMBL ID1518220
SCHEMBL ID222283
MeSH IDM0536194

Synonyms (114)

Synonym
AC-2537
brn 0879619
ccris 1978
naphthoelan red b base
ai3-02919
aniline, 2-methoxy-4-nitro-
2-methoxy-4-nitrobenzenamine
2-amino-5-nitroanisol [czech]
einecs 202-588-6
nsc 4130
AKOS015831339
nsc-4130
symulon red b base
fast red 5na base
2-methoxy-4-nitroaniline
amarthol fast red b base
brentamine fast red b base
dainichi fast red b base
4-amino-3-methoxynitrobenzene
kako red b base
azoene fast red b base
naphthanil red b base
red base nb
4-nitro-6-methoxyaniline
mitsui red b base
97-52-9
diabase red b
red base ciba v
c.i. 37125
wln: wnr dz c01
azoic diazo component 5, base
showa fast red b base
2-amino-5-nitroanisole
4-nitro-o-anisidine
5-nitro-2-anisidine
o-anisidine, 4-nitro-
pnoa
sanyo fast red b base
fast red base b
nsc4130
red base irga v
p-nitro-o-anisidine
red b base
2-amino-1-methoxy-5-nitrobenzene
2-amino-5-nitroanisol
azoamine pink o
hiltonil fast red b base
diazo fast red b
c.i. azoic diazo component 5
naphtoelan red b base
anisole, 2-amino-5-nitro-
benzenamine, 2-methoxy-4-nitro-
shinnippon fast red b base
daito red base b
fast red b
fast red b base
devol red e
kayaku red b base
AQ-776/40179312
smr000184317
MLS000569544
(2-methoxy-4-nitrophenyl)amine
inchi=1/c7h8n2o3/c1-12-7-4-5(9(10)11)2-3-6(7)8/h2-4h,8h2,1h
GHL.PD_MITSCHER_LEG0.1089
2-methoxy-4-nitroaniline, 98%
1-amino-2-methoxy-4-nitrobenzene
M0118
AKOS000120376
A19843
4-nitro-o-anisidine; c.i. 37125
NCGC00245538-01
HMS2533D12
ec 202-588-6
unii-dpu26p1846
dpu26p1846 ,
dtxcid8018700
dtxsid0038700 ,
tox21_302128
NCGC00255414-01
cas-97-52-9
brilliant red developing base 4b
ci 37125
2-methoxy-4-nitro-phenylamine
BP-20432
FT-0612797
PS-3009
AM20060763
SCHEMBL222283
BBL027639
2-methoxy-4-nitro-aniline
4-nitro-1-amino-2-methoxybenzene
2-methoxy-4nitro-aniline
2-methoxy4-nitroaniline
AKOS024268499
azoic diazo component 5
fast red b-t base
3-nitro-6-aminoanisole
cambridge id 5102825
W-100105
CHEMBL1518220
nitro-o-anisidine, 4-
ci azoic diazo component 5
4-nitro-2-methoxyaniline
3-methoxy-4-aminonitrobenzene
o-methoxy-p-nitroaniline
F2146-0313
mfcd00007363
EN300-20366
STL194282
E78874
Q27276523
2-methoxy-4-nitroaniline/ masculineie<<>>ub
2-methoxy-4-nitro aniline
Z104477890

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" MNA was well-absorbed in rats and mice following oral administration and eliminated chiefly in urine (rats, 75-79%; mice, 55-68%) 72 h post dosing."( Metabolism and disposition of 2-methoxy-4-nitroaniline in male and female Harlan Sprague Dawley rats and B6C3F1/N mice.
Banks, TT; Black, SR; Burgess, JP; Etheridge, AS; Fennell, TR; Mathews, JM; Patel, PR; Snyder, RW; Surh, I; Waidyanatha, S; Warren, SD; Zhan, Q, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" B6C3F1/N mice were exposed to 0, 650, 1250, 2500, 5000, or 10,000 ppm MNA by dosed feed for 14-days to evaluate subacute toxicity and histopathological endpoints."( Evaluation of 2-methoxy-4-nitroaniline (MNA) in hypersensitivity, 14-day subacute, reproductive, and genotoxicity studies.
Auerbach, SS; Buccellato, M; Cunny, H; Fallacara, D; Frawley, RP; Germolec, DR; Harris, S; Jackson-Humbles, D; Kissling, GE; Malarkey, D; Manheng, W; Shockley, KR; Stout, M; Surh, II; Travlos, G; White, K; Witt, KL, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency70.97990.002541.796015,848.9004AID1347397; AID1347399
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686979
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency15.79420.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency34.37620.000417.946075.1148AID1346795
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.33650.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.10750.000229.305416,493.5996AID1259244; AID743069; AID743078
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
histone deacetylase 9 isoform 3Homo sapiens (human)Potency68.58960.037617.082361.1927AID1259364
huntingtin isoform 2Homo sapiens (human)Potency0.63100.000618.41981,122.0200AID1688
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency22.38720.00419.962528.1838AID2675
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.30600.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.30600.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's7 (58.33)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.56 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]